{"id":4300,"date":"2026-10-12T08:32:38","date_gmt":"2026-10-12T08:32:38","guid":{"rendered":"https:\/\/nhdbio.com\/?p=4300"},"modified":"2026-10-12T08:32:38","modified_gmt":"2026-10-12T08:32:38","slug":"selectivite-mc4r-peptides-de-pigmentation-mc1r","status":"publish","type":"post","link":"https:\/\/nhdbio.com\/fr\/mc4r-selectivity-mc1r-pigmentation-peptides\/","title":{"rendered":"Candidats \u00e0 la perte de poids MC4R : pourquoi la pigmentation de la peau importe-t-elle ?"},"content":{"rendered":"
\n
\"Themed
Editorial illustration, not an experimental photograph.<\/figcaption><\/figure>\n

Researchers want weight-loss signals to be more precise, and they also want to reduce unwanted effects. The recent candidate progress announced by Palatin involves a very intuitive question: how can a molecule that acts on appetite avoid affecting skin pigmentation at the same time as much as possible?<\/p>\n

\n

The two receptors have similar names, but different jobs<\/h2>\n

MC4R is involved in energy balance and appetite regulation, while MC1R is related to skin pigmentation. When studying a molecule that acts on melanocortin receptors, it is necessary to see which receptors it actually touches.<\/p>\n

You can think of it as a set of keys: if you want to open one lock, you also need to check whether it happens to open the lock next to it. What is called "selectivity" here means acting on the target receptor as much as possible and reducing effects on other receptors.<\/p>\n<\/section>\n

\n

What exactly did the update on September 28 say?<\/h2>\n

The company says that some peptide candidates with fatty chains added and without fatty chains added showed strong agonist activity at MC4R in testing, but did not behave as MC1R agonists. This provides a research and development basis for reducing pigmentation.[1]<\/a><\/p>\n

"no MC1R agonist activity was observed" refers to results under the corresponding experimental conditions. It still cannot replace actual observations in humans of skin color, adverse reactions, and long-term safety.<\/p>\n<\/section>\n

\n

Why add a fatty chain?<\/h2>\n

Peptides may be cleared quickly in the body. Adding an appropriate fatty chain is one way researchers explore extending the duration of action, but it also changes binding, distribution, and formulation properties.[1]<\/a><\/p>\n

Therefore, adding a fatty chain is not simply a way to make a molecule "more advanced." It must be tested together with receptor activity, stability, and exposure to know whether it truly supports fewer doses.<\/p>\n<\/section>\n

\n

Weekly injection and oral administration have different development timelines<\/h2>\n

The public update proposed that the phase one trial goal for the weekly injection candidate is the first half of 2027; the phase one goal for the oral candidate is the second half of 2027. The company also mentioned conditions such as funding needs.<\/p>\n

These are planned timelines, not results that have already started and been completed. Even if both target MC4R, oral and injection still have different absorption and formulation issues, and progress in one route cannot be counted as progress in the other.<\/p>\n<\/section>\n

\n

Which studies can better test this idea?<\/h2>\n

The next step is to look at human exposure, tolerability, skin color changes, and whether credible signals appear for appetite and body weight. Early receptor experiments can help select molecules, but the real clinical results still must come from later trials.<\/p>\n

This news is suitable for understanding receptor selectivity and long-acting modification. It is not proof that an old catalog product in the melanocortin class has obtained a new weight-loss indication.<\/p>\n<\/section>\n

\n

Why does the skin pigmentation issue require receptor experiments?<\/h2>\n

Pigment changes may involve multiple processes. First checking the candidate's activity at MC1R can help screen molecules, and afterward real exposure and human observations are still needed. The two steps each provide different information.<\/p>\n

When developing long-acting peptides, solubility, stability, and impurities are also monitored at the same time. After improving one property, it should be checked whether other properties have been sacrificed. Conclusions about a material cannot be based only on being "long-acting."<\/p>\n<\/section>\n